The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy

Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy

November 18, 2016 • By Megan Brooks

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Patients with active rheumatoid arthritis (RA) and no known heart disease may have subclinical myocardial inflammation, which improves with disease-modifying therapy, new research shows.

You Might Also Like
  • Myocardial Inflammation Associated with RA Disease Activity
  • More Evidence Biomarkers Predict RA Relapse with DMARD Taper
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
Also By This Author
  • Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

“We know that patients with RA have higher risk of cardiovascular events, including heart failure and we really don’t know why. Maybe myocardial inflammation is one of the mechanisms,” lead author Dr. Isabelle Amigues of Columbia University in New York noted in a phone interview with Reuters Health.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Despite the many advances of rheumatology care, this study shows there is inflammation of the heart that we can actually see on the PET scan. This is important,” Dr. Amigues said, “because as a clinician with a patient who has high disease activity, I can tell them, this is not just about your joints, it’s also about your heart.”

Dr. Amigues presented the findings November 14 at the American College of Rheumatology annual meeting in New Orleans.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

She and her colleagues investigated the prevalence of myocardial inflammation in 118 RA patients without prior CVD events and 13 well-matched controls without RA.

The RA patients had a mean age of 55 years, a mean BMI of 28.5 and their median disease duration was seven years. The patients had a mean disease activity score in 28 joints (DAS28) of 3.78, and 28% had Clinical Disease Activity Index (CDAI) less than 10, consistent with low disease activity or remission. Forty-five patients used biologics, primarily TNF inhibitors (TNFi).

Using cardiac FDG-PET-CT imaging that can detect inflammation in the myocardium, the researchers compared mean maximal standardized uptake value (SUVmax) for myocardial FDG uptake to disease activity scores.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Median SUVmax was 12% higher in the RA patients relative to control patients.

In RA patients, higher BMI and moderate-to-severe disease activity were positively associated with SUVmax. After adjusting for BMI and RA therapy, mean SUVmax was 30% higher in patients with moderate-to-severe disease activity compared with to those with low disease activity.

RA patients treated with a non-TNFi biologic had a 35% lower mean SUVmax compared to those either not on a biologic or on a TNFi. “It seems that disease activity is linked to higher inflammation,” Dr. Amigues told Reuters Health.

“This is the first report of a quantitative assessment of myocardial inflammation and the largest number of RA patients ever studied for myocardial inflammation,” Dr. Joan M. Bathon, director of rheumatology at Columbia, said in a news release.

She said the link between myocardial inflammation and articular inflammation is compelling, as it suggests that treating the joint inflammation might also lessen myocardial inflammation.

Pages: 1 2 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Rheumatoid Arthritis Tagged With: American College of Rheumatology annual meeting, DMARD, myocardial inflammation, RA, Rheumatoid arthritis

You Might Also Like:
  • Myocardial Inflammation Associated with RA Disease Activity
  • More Evidence Biomarkers Predict RA Relapse with DMARD Taper
  • Certolizumab Pegol Combination Therapy Better than Methotrexate Monotherapy in DMARD-Naive Patients with RA
  • Therapies Aimed at Immune Cell Progenitors May Be Key to Reducing Post Myocardial Infarction Risk

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)